Q4 2024 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2025-02-14 · accession 0000905148-25-000652
$170.7M
Reported value
7
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | PHARVARIS N V | $82.2M | 48.2% | 4,289,304 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $21.9M | 12.8% | 2,787,398 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $18.6M | 10.9% | 539,194 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $16.2M | 9.49% | 9,699,925 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $15.3M | 8.98% | 1,519,971 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $12.0M | 7.00% | 3,806,410 | Common | SOLE |
| 55083R104 | — | LYELL IMMUNOPHARMA INC | $4.5M | 2.66% | 7,102,190 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.